NCT06943755 2026-02-27
STELLAR-311
Exelixis
Phase 2/3 Recruiting
Clinical Trials
10 trialsNCT07165886 2025-09-10
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3 Recruiting
NCT06855095 2025-03-03
ATSA
The Netherlands Cancer Institute
Phase 2/3 Recruiting
NCT05749289 2024-03-29
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Recruiting
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT03590119 2022-11-08
LUTIA
UMC Utrecht
Phase 2/3 Completed
NCT02608203 2022-10-14
GEP-NOC
Assistance Publique Hopitaux De Marseille
Phase 2/3 Completed
NCT04552847 2022-02-17
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven
Phase 2/3 Completed
NCT01744249 2021-02-02
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
Phase 2/3 Unknown